Form 6-K — CureVac N.V.: Interim Condensed Consolidated Financial Statements as of March 31, 2022
Summary
A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission for the month of May 2022, Commission File Number 001-39446. It states that the report is furnished for the sole purposes of providing Exhibit 99.1, unaudited interim condensed consolidated financial statements as of March 31, 2022 and December 31, 2021, and Exhibit 99.2, Management's Discussion and Analysis of Financial Condition and Results of Operations. The exhibit index lists those exhibits, and the report is incorporated by reference into Form F-3, File No. 333-259613. It is signed May 25, 2022.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Form 6-K — CureVac N.V.: Interim Condensed Consolidated Financial Statements as of March 31, 2022.”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-cvac-6-k-filed2022-05-25-0001410578-22-001837-1d66a693c0/
, SHA-256 cd30973aee61771c190630468e5890de51496c77254e7a36c1c020c487c54429.Full text
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of May 2022
Commission File Number: 001-39446
CureVac N.V.
( Exact Name of Registrant as Specified in Its Charter )
Friedrich-Miescher-Strasse 15, 72076
Tübingen, Germany
+49 7071 9883 0
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F | ⌧ | Form 40-F | ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes | ☐ | No | ⌧
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes | ☐ | No | ⌧
This Report of Foreign Private Issuer on Form 6-K (this "Form 6-K") is being furnished by CureVac N.V. ("CureVac") to the Securities and Exchange Commission (the "SEC") for the sole purposes of: (i) furnishing, as Exhibit 99.1 to this Form 6-K, Unaudited Interim Condensed Consolidated Financial Statements announcing CureVac's financial results and business updates as of March 31, 2022 and December 31, 2021 and for the three month periods ended March 31, 2022 and 2021; (ii) furnishing, as Exhibit 99.2 to this Form 6-K, Management's Discussion and Analysis of Financial Condition and Results of Operations, which discusses and analyzes CureVac's financial condition and results of operations as of March 31, 2022 and December 31, 2021 and for the three month periods ended March 31, 2022 and 2021;
The information included in this Form 6-K (including Exhibits 99.1 and 99.2) is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CUREVAC N.V.
By: | /s/ Franz-Werner Haas, LLD, LLM
Chief Executive Officer
Date: May 25, 2022
EXHIBIT INDEX
EXHIBIT NO. | DESCRIPTION
99.1 | Unaudited Interim Condensed Consolidated Financial Statements as of March 31, 2022 and for the three month periods ended March 31, 2022 and 2021
99.2 | Management’s Discussion and Analysis of Financial Condition and Results of Operations
File and source
- File
- SEC_CVAC_6-K_filed2022-05-25_0001410578-22-001837.htm
- Size
- 97,312 bytes
- SHA-256
- cd30973aee61771c190630468e5890de51496c77254e7a36c1c020c487c54429
- Original
- www.sec.gov